MYH6
ENSG00000197616
Target class
Unclassified protein
Chromosome
14
Approved drugs
1
Clinical candidates (approved and in development)
3
- Approved drugs
- 1
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 3
- Chemical probe available
- No
- Target name
- MYH6
- Gene name
- Myosin heavy chain 6
- Gene symbol
- MYH6
- Protein name
- Myosin-6 (Myosin heavy chain 6) (Myosin heavy chain, cardiac muscle alpha isoform) (MyHC-alpha)
- Gene biotype
- Protein coding
- Gene family
- Myosin heavy chains, class II|MicroRNA protein coding host genes
- Target class
- Unclassified protein
- Target type
- Human gene
- Tissues expressed in
- 4
- Protein localisation evidence grade
- Uncertain
- Highest tissue expression
- 4,609.46
- Tissue specificity (Gini)
- 0.975
- Tissue specificity (tau)
- 0.998
- KEGG gene identifiers
- hsa:4624
- Reactome pathways
- R-HSA-390522
- Protein interaction confidence
- 0.836203
- Protein interaction partners
- 69
- End position
- 23408945
- Start position
- 23381576
- Chromosome
- 14
- Strand
- Reverse
- Cytoplasm, myofibril. Note=Thick filaments of the myofibrils.
- Tissue specificity (tau)
- 0.998319
- Expression inequality (Gini)
- 0.975369
Expression in transcripts per million
- Heart - Atrial Appendage
- 4,609.46
- Heart - Left Ventricle
- 334.6
- Muscle - Skeletal
- 53.32
- Pituitary
- 5.65
- Prostate
- 0.68
Expression in transcripts per million
- Heart - Atrial Appendage4,609.46
- Heart - Left Ventricle334.6
- Muscle - Skeletal53.32
- Pituitary5.65
- Prostate0.68
- Artery - Coronary0.68
- Nerve - Tibial0.62
- Lung0.59
- Skin - Not Sun Exposed (Suprapubic)0.54
- Artery - Tibial0.54
- Vagina0.53
- Skin - Sun Exposed (Lower leg)0.53
- Minor Salivary Gland0.52
- Colon - Sigmoid0.52
- Thyroid0.52
- Esophagus - Gastroesophageal Junction0.49
- Cells - EBV-transformed lymphocytes0.48
- Artery - Aorta0.47
- Esophagus - Muscularis0.46
- Adipose - Visceral (Omentum)0.46
- Testis0.43
- Adipose - Subcutaneous0.42
- Brain - Cortex0.4
- Uterus0.4
- Breast - Mammary Tissue0.38
And 29 more, listed on the interactive page.
- GO:0002026
- GO:0002027
- GO:0006936
- GO:0006941
- GO:0007512
- GO:0030049
- GO:0046034
- GO:0055009
- GO:0055010
- GO:0005829
- GO:0005859
- GO:0016459
- GO:0030017
- GO:0000146
- GO:0017018
- GO:0019901
Related records
Trials (65)
- A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM
- A Pharmacokinetic and Pharmacodynamic Study of Omecamtiv Mecarbil in Healthy Volunteers
- A Phase 2 Open-label Pilot Study Evaluating MYK-461 in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction
- A Phase 2 Study of Mavacamten in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)
- A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)
- A Retrospective Cohort Study of Mavacamten Patient Support Program in Canada
- A Study of CK-1827452 Infusion in Stable Heart Failure
- A Study of Mavacamten in Adults With Obstructive Hypertrophic Cardiomyopathy in India (ROVER)
- A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy
- A Study of Mavacamten in Obstructive Hypertrophic Cardiomyopathy
- A Study of Mavacamten in Participants With HFpEF and Elevation of NT-proBNP With or Without Elevation of cTnT
- A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy
- A Study of the Long-term Safety and Efficacy of Danicamtiv in Adults With Symptomatic Genetic and Familial Dilated Cardiomyopathy
- A Study to Assess the Effect of Danicamtiv on the Drug Levels of Midazolam in Participants With Stable Heart Failure
- A Study to Assess the Effects on the Single-Dose Drug Levels of Mavacamten in Healthy Participants
- A Study to Assess the Real-World Effectiveness of Mavacamten in Adult Patients With Obstructive Hypertrophic Cardiomyopathy in China
- A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants
- A Study to Assess the Safety of Mavacamten in Korean Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy
- A Study to Assess the Treatment of Obstructive Hypertrophic Cardiomyopathy (oHCM) With Mavacamten in the US
- A Study to Evaluate Mavacamten Impact on Myocardial Structure in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Drugs (3)
- Danicamtiv Cardiac myosin activator
- Mavacamten Cardiac myosin inhibitor
- Omecamtiv mecarbil Cardiac myosin activator